Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Rapamycin Longevity Lab
- Ownership
- Private
- Development stage
- Other
01
Overview
Rapamycin Longevity Lab is a biotechnology company focused on the development and optimization of rapamycin-based therapies to promote longevity and treat age-related diseases. The company leverages the well-documented effects of rapamycin on the mTOR pathway to explore new formulations and dosing regimens aimed at extending healthy lifespan. Their research emphasizes the translation of geroscience into clinical applications, targeting the biological drivers of aging. By focusing on small molecule modulation of nutrient-sensing pathways, the lab seeks to mitigate the onset of chronic conditions associated with getting older.
- Therapeutic areas
- Other
- Modalities
- Small molecule
- Industry
- Biotech
Beyond the preview
Go deeper on Rapamycin Longevity Lab.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Rapamycin Longevity Lab.